Abstract
Introduction

Interstitial pneumonia is frequently identified in patients with polymyositis and dermatomyositis (1). Amyopathic dermatomyositis (ADM) is a clinical subtype of dermatomyositis characterized by the absence of a motor weakness and the presence of normal muscle enzyme levels (2, 3). Other studies, primarily from Asia, have demonstrated that some patients with ADM develop rapidly progressive interstitial pneumonia that remains unresponsive to intensive therapy, such as high-dose corticosteroids plus immunosuppressive agents, leading to fatal respiratory failure
. No proven treatment has yet been reported previously. Here, we describe a patient with rapidly progressive interstitial pneumonia accompanied by clinically ADM (C-ADM) (3, 9) , who was treated successfully with polymyxin B-immobilized fiber column (PMX) hemoperfusion. (Fig. 4) . Complication with malignant tumor was not found on the examinations performed after his improvement. Chest radiography and HRCT showed remarkable improvement after 5 months of the treatment (Fig. 5) , and the patient survived for over 6 months after PMX treatment.
Case Report
A
Discussion
Polymyositis/dermatomyositis is frequently accompanied by interstitial pneumonia which is known as a significant prognostic factor in this disease (10) . C-ADM, which shows 
t i o n ( F i O2 ) r a t i o , L DH: l a c t a t e d e h y d r o g e n a s e .
F i g u r e 3 . P / F r a t i o a n d Aa DO2 b e f o r e a n d a f t e r P MX t h e r a p y . (3, 9, 11, 12) 
Ar t e r i a l o x y g e n t e n s i o n ( P a O2 ) / i n s p i r a t o r y o x y g e n f r a c t i o n ( F i O2 ) ( P / F ) r a t i o ( A) a n d a l v e o l a r -a r t e r i a l d i f f e r e n c e o f o x y g e n ( Aa DO2 ) ( B ) a r e o b v i o u s l y i mp r o v e d .
lack of motor weakness, presence of normal muscle enzyme levels and negative tests for anti-Jo-1 antibody, is associated with rapidly fatal progressive interstitial pneumonia, especially among Japanese patients
. Such patients are often resistant to intensive therapy, such as high-dose corticosteroids plus immunosuppressive agents, resulting in fatal respiratory failure (4-8). There is no proven treatment and mortality rates are high (50% or more), with most deaths occurring between the first and the second months of illness onset (13). Recent reports have suggested that PMX might improve oxygenation in patients with acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) (14-17). Seo et al recently reported that 4 of 6 patients with acute exacerbation
F i g u r e 4 . Cl i n i c a l c o u r s e a f t e r e x t u b a t i o n . P S L : p r e d n i s o l o n e , Cy A: c y c l o s p o r i n e A, S P -A: s u rf a c t a n t p r o t e i n -A, S P -D: s u r f a c t a n t p r o t e i n -D.
F i g u r e 5 . T h e c h e s t i ma g e s o f t h e p a t i e n t a f t e r 5 mo n t h s o f P MX t h e r a p y . Ch e s t r a d i o g r a p h y ( A) a n d HRCT ( B a n d C) s h o w r e ma r k a b l e i mp r o v e me n t . of idiopathic pulmonary fibrosis were weaned from mechanical ventilation and survived for over 30 days after initial PMX treatment (18). Noma et al also recently reported that PMX treatment was effective in two patients with acute exacerbation of interstitial pneumonia (19). Although the present patient was resistant to steroid therapy, progressed rapidly and required mechanical ventilation, PMX was very effective and the patient survived for over 6 months after admission. The present case together with those of others suggest that direct hemoperfusion with PMX could be effective against rapidly progressive interstitial pneumonia which is resistant to conventional therapy such as high-dose corticosteroids plus immunosuppressive agents.
As PMX potentially absorbs plasma endotoxin, this therapy is mainly used to treat septic shock as it results in decreased plasma endotoxin levels and improved hemodynamic stability (20) . Aoki et al have suggested that reducing the endotoxin concentration might reduce pulmonary vasoconstriction and intrapulmonary shunting (17) . However, PMX is effective against both gram-negative and gram-positive sepsis (17 (15) . In an animal model of sepsis, PMX improves oxygenation through the suppression of nitric oxide production (21) . Kushi (26) . A recent paper has suggested that more frequent applications will be effective against severe sepsis (27) . Seo 
